Powering protein degradation for tomorrow’s medicines. "We are changing the limits of what is possible in medicine. Our vision is to provide a remedy for debilitating diseases that lack effective treatments."Ying Luo, Ph.D. - C.E.O. More About Us Expanding the drug design paradigm Targeted Protein Degraders: The ability to drug the “undruggable.” Learn About the Science uSMITE™ Our innovative protein degradation technology featuring novel E3 ligands. Our Platform We build the world’s most robust protein degraders using our novel E3 ligands for the treatment of cancer and other debilitating diseases. Our Pipeline Latest News January 16, 2024 CULLGEN ANNOUNCES ADDITIONS TO BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD October 15, 2023 CULLGEN AND ASTELLAS HONORED WITH 2023 LES DEALS OF DISTINCTION AWARD July 27, 2023 CULLGEN ANNOUNCES FIRST-IN-HUMAN DOSE IN PHASE I/II TRIAL OF CG001419, A FIRST-IN-CLASS TRK PROTEIN DEGRADER FOR TREATMENT OF CANCER PATIENTS See All